(Q43034842)

12 November 2017

title

Therapy for chronic hepatitis C. (English)

1 reference

12 November 2017

A Pár

1

1 reference

12 November 2017

L Telegdy

2

1 reference

12 November 2017

L Dalmi

3

1 reference

12 November 2017

E Müller

4

1 reference

12 November 2017

Hungarian Viral Hepatitis Treatment Study Group

5

1 reference

12 November 2017

publication date

1 January 2001

1 reference

Journal of Physiology (Paris)

12 November 2017

published in

1 reference

12 November 2017

volume

95

1 reference

12 November 2017

issue

1-6

1 reference

12 November 2017

page(s)

399-405

1 reference

https://api.crossref.org/works/10.1016%2FS0928-4257%2801%2900054-7

12 November 2017

1 reference

7 January 2021

Epidemiology of hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0928-4257%2801%2900054-7

7 January 2021

Pathogenesis, diagnosis and management of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0928-4257%2801%2900054-7

7 January 2021

Factors predictive of a beneficial response to therapy of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0928-4257%2801%2900054-7

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0928-4257%2801%2900054-7

7 January 2021

Hepatitis C virus infection: quality of life and side effects of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0928-4257%2801%2900054-7

7 January 2021

Clinical outcome of hepatitis C as a function of mode of transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0928-4257%2801%2900054-7

7 January 2021

Therapy of viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0928-4257%2801%2900054-7

7 January 2021

Treatment of chronic hepatitis C with high-dose interferon alpha-2b. A multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0928-4257%2801%2900054-7

7 January 2021

10-Year follow-up after interferon-alpha therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0928-4257%2801%2900054-7

7 January 2021

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0928-4257%2801%2900054-7

7 January 2021

Predictors of sustained response to alpha interferon therapy in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0928-4257%2801%2900054-7

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0928-4257%2801%2900054-7

7 January 2021

Prognosis of chronic hepatitis C: results of a large, prospective cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS0928-4257%2801%2900054-7

7 January 2021

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0928-4257%2801%2900054-7

7 January 2021

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0928-4257%2801%2900054-7

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0928-4257%2801%2900054-7

7 January 2021

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0928-4257%2801%2900054-7

7 January 2021

Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0928-4257%2801%2900054-7

7 January 2021

Clinical outcomes after transfusion-associated hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0928-4257%2801%2900054-7

7 January 2021

Treatment of naive patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0928-4257%2801%2900054-7

7 January 2021

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0928-4257%2801%2900054-7

7 January 2021

Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0928-4257%2801%2900054-7

7 January 2021

10.1016/S0928-4257(01)00054-7

Identifiers

DOI

1 reference

release_qhm7l4de7bbp5ptrmvbhwuut54

12 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qhm7l4de7bbp5ptrmvbhwuut54

24 November 2022

mapped directly with Wikidata item

1 reference